Project Grant R21CA304932
Award Date 6/8/26
Completion Date 5/31/28
Dollars Obligated $419K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Emigration Canyon, UT 84108, USA
Similar Awards
- Federal Grant Award Summary Primary Bioscience, Inc. received a $305,000 Small Business Technology Transfer (STTR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) effective July 15, 2025, with a completion date of June 30, 2026. The company is developing an ultra-sensitive biosensor capable of single-molecule protein analysis and sequencing. The technology integrates a nanopatterned chip with a proprietary amino acid and...
- Grant Award Summary The National Cancer Institute (NCI) awarded a $450,904 Project Grant to the Pacific Northwest National Laboratory (PNNL), a division of Battelle Memorial Institute, under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. The funded project will develop a novel single-cell (phospho-)proteomics platform designed to characterize tumor microenvironment (TME) components—including cancer cells, immune cells, and stromal...
- Federal Project Grant Award Summary Sinopia Biosciences Inc. received a $285,599 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on September 22, 2025, with a completion date of August 31, 2027. The award supports the development of a metabolomics-enabled artificial intelligence/machine learning (AI/ML) platform designed to discover new treatments that enhance drug sensitivity in cancer. Working in collaboration with Omix...
- Federal Project Grant Award Summary The National Cancer Institute awarded $270,683 to the New York Genome Center, Inc. under the Cancer Biology Research program (CFDA 93.396) on May 5, 2026, for development and validation of Paired-Break-Seq, a novel single-cell multiomics sequencing technique. This three-year project, concluding April 30, 2029, will deliver a high-throughput method enabling joint analysis of double-stranded DNA breaks (DSBs), single-stranded DNA breaks (SSBs), and transcriptome...
- Federal Project Grant Award Summary Panome Bio Inc. received an $881,647 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and commercialize advanced untargeted metabolomics services for colon cancer biomarker discovery. The project, which commenced September 2, 2025, and concludes August 31, 2027, focuses on addressing critical limitations in current metabolomics software that impede widespread adoption of...
- Federal Grant Award Summary Newomics Inc. received a $1.0 million Small Business Innovation Research (SBIR) Phase II Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2027. The award funds the development and commercialization of the UniESI platform, an integrated imaging-mass spectrometry front-end system designed for native spray mass...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary Piccolo Biosystems, Inc. received a $295,861 Phase I Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2026. In collaboration with the University of Washington, Piccolo will develop and validate an innovative ultra-small scale assay platform for measuring enzyme inhibition, specifically...
- Federal Grant Award Summary Nanoprobes Inc. received a $613,744 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through February 28, 2027. The award supports the development of combined fluorescent and gold nanoparticle labeling reagents designed to advance correlative light and electron microscopy (CLEM) research. The project addresses a critical gap in...
- Federal Project Grant Award Summary Chemia Biosciences, Inc. received a $781,502 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to develop NatDiscovery, a computational platform for identifying novel non-ribosomal peptides from complex mass spectrometry datasets. The award, effective July 1, 2025 through June 30, 2028, supports the integration of genome mining with computational...